BAYER AG: US FDA APPROVED KERENDIA TO TREAT PATIENTS WITH HEART FAILURE WITH LEFT VENTRICULAR EJECTION FRACTION ≥40%
Further company coverage: [BAYGn.DE]
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.